Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone

Journal of Pediatrics

Volumn 148, Issue 3, 2006, Pages 386-388

  Johnson, Susan R ^a   Marion, Alicia A ^a   Vrchoticky, Teri ^a   Emmanuel, Patricia J ^a   Lujan Zilbermann, Jorge ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CORTICOTROPIN; COTRIMOXAZOLE; DEXAMETHASONE; DIDANOSINE; EFAVIRENZ; FLUCONAZOLE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; HYDROCORTISONE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MONTELUKAST; PREDNISOLONE; RITONAVIR; SALBUTAMOL; SALMETEROL; STAVUDINE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG DERIVATIVE; PROTEINASE INHIBITOR;

ABDOMEN; ADOLESCENT; ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ANOREXIA; ARTICLE; ASTHMA; BRONCHIECTASIS; CAPILLARY RESISTANCE; CASE REPORT; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; CUSHINGOID SYNDROME; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; EPIGASTRIC PAIN; FEMALE; HIRSUTISM; HORMONE SUBSTITUTION; HOSPITAL DISCHARGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; LABORATORY TEST; LIVEDO RETICULARIS; MALAISE; NAUSEA; OBESITY; PNEUMOCYSTIS PNEUMONIA; POLYURIA; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; STEROID THERAPY; STRIA; TETANY; THROMBOCYTOPENIA; THRUSH; TREATMENT OUTCOME; VIRUS LOAD; VOMITING; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; CHILD; DRUG COMBINATION; DRUG INTERACTION; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL INSUFFICIENCY; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CUSHING SYNDROME; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; RITONAVIR;

EID: 33646016085     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2005.11.034     Document Type: Article

References (12)

1. Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy. a systematic review and meta-analysis. Arch Intern Med 159 (1999) 941-955
2. Barnes P.J. Inhaled glucocorticoids for asthma. N Engl J Med 332 (1995) 368-375
3. Chen F., Kearney T., Robinson S., Daley-Yates P.T., Waldron S., and Churchill D.R. Cushing syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect 75 (1999) 274
4. Samaras K., Pett S., Gowers A., McMurchie M., and Cooper D.A. Iatrogenic Cushing syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors. six cases. J Clin Endocrinol Metab 90 (2005) 4394-4398
5. Clevenbergh P., Corcostegui M., Gérard D., Hieronimus S., Mondain V., Chichmanian R.M., et al. Iatrogenic Cushing syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen. J Infect 44 (2002) 194-195
6. Gillett M.J., Cameron P.U., Nguyen H.V., Hurley D.M., and Mallal S.A. Iatrogenic Cushing syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone. AIDS 19 (2005) 740-741
7. Gupta S.K., and Dubé M.P. Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy. Clin Infect Dis 35 (2002) E69-E71
8. Hillebrand-Haverkort M.E., Prummel M.F., and ten Veen J.H. Ritonavir-induced Cushing syndrome in a patient treated with nasal fluticasone. AIDS 13 (1999) 1803
9. Soldatos G., Sztal-Mazer S., Woolley I., and Stockigt J. Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction. Intern Med J 35 (2005) 67-68
10. Sagir A., Wettstein M., Oette M., Erhardt A., and Häussinger D. Budesonide-induced acute hepatitis in a HIV-positive patient with ritonavir as a co-medication. AIDS 16 (2002) 1191-1192
11. U.S. Food and Drug Administration [homepage on the Internet]. Rockville: Department of Health and Human Services; [updated 2004, Apr 19; cited 2004 Mar]. The FDA Safety Information and Adverse Event Reporting Program; [1 screen]. Available from: http://www.fda.gov/Medwatch/Safety/2004/Mar04.htm
12. Webb J., and Clark T.J. Recovery of plasma corticotrophin and cortisol levels after three-week course of prednisolone. Thorax 36 (1981) 22-24